These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26191652)

  • 1. Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice.
    Koh JS; Yi CO; Heo RW; Ahn JW; Park JR; Lee JE; Kim JH; Hwang JY; Roh GS
    Free Radic Biol Med; 2015 Dec; 89():54-61. PubMed ID: 26191652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.
    Chen YL; Chung SY; Chai HT; Chen CH; Liu CF; Chen YL; Huang TH; Zhen YY; Sung PH; Sun CK; Chua S; Lu HI; Lee FY; Sheu JJ; Yip HK
    J Pharmacol Exp Ther; 2015 Dec; 355(3):516-27. PubMed ID: 26511374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Betaine ameliorates doxorubicin-induced cardiomyopathy by inhibiting oxidative stress, inflammation, and fibrosis through the modulation of AMPK/Nrf2/TGF-β expression.
    Singh SK; Yadav P; Patel D; Tanwar SS; Sherawat A; Khurana A; Bhatti JS; Navik U
    Environ Toxicol; 2024 Aug; 39(8):4134-4147. PubMed ID: 38651543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis.
    Mantawy EM; El-Bakly WM; Esmat A; Badr AM; El-Demerdash E
    Eur J Pharmacol; 2014 Apr; 728():107-18. PubMed ID: 24509133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
    Mohamed HE; Asker ME; Ali SI; el-Fattah TM
    J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction.
    Tian XQ; Ni XW; Xu HL; Zheng L; ZhuGe DL; Chen B; Lu CT; Yuan JJ; Zhao YZ
    Int J Nanomedicine; 2017; 12():7103-7119. PubMed ID: 29026304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
    Koka S; Das A; Zhu SG; Durrant D; Xi L; Kukreja RC
    J Pharmacol Exp Ther; 2010 Sep; 334(3):1023-30. PubMed ID: 20543097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
    Sakurada M; Yoshimoto T; Sekizawa N; Hirono Y; Suzuki N; Hirata Y
    Hypertens Res; 2010 Mar; 33(3):229-35. PubMed ID: 20019701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy.
    Chen X; Chen Y; Bi Y; Fu N; Shan C; Wang S; Aslam S; Wang PW; Xu J
    Cardiovasc Drugs Ther; 2007 Oct; 21(5):367-74. PubMed ID: 17924179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling.
    Thandavarayan RA; Giridharan VV; Arumugam S; Suzuki K; Ko KM; Krishnamurthy P; Watanabe K; Konishi T
    PLoS One; 2015; 10(3):e0119214. PubMed ID: 25742619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats.
    Chang SA; Lim BK; Lee YJ; Hong MK; Choi JO; Jeon ES
    J Korean Med Sci; 2015 May; 30(5):559-68. PubMed ID: 25931786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy.
    Hamed S; Barshack I; Luboshits G; Wexler D; Deutsch V; Keren G; George J
    Eur Heart J; 2006 Aug; 27(15):1876-83. PubMed ID: 16731534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
    Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by irbesartan to ameliorate doxorubicin-induced hepatotoxicity.
    Kabel AM; Alzahrani AA; Bawazir NM; Khawtani RO; Arab HH
    J Infect Chemother; 2018 Aug; 24(8):623-631. PubMed ID: 29753615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to protect doxorubicin-induced cardiomyopathy in male albino rats?
    Shaker O; Sourour DA
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):262-8. PubMed ID: 20051877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice.
    Riad A; Bien S; Westermann D; Becher PM; Loya K; Landmesser U; Kroemer HK; Schultheiss HP; Tschöpe C
    Cancer Res; 2009 Jan; 69(2):695-9. PubMed ID: 19147586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin- and trastuzumab-mediated cardiomyopathy.
    Zeglinski M; Premecz S; Lerner J; Wtorek P; Dasilva M; Hasanally D; Chaudhary R; Sharma A; Thliveris J; Ravandi A; Singal PK; Jassal DS
    Can J Cardiol; 2014 Mar; 30(3):359-67. PubMed ID: 24484915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats.
    Mounier NM; Wahdan SA; Gad AM; Azab SS
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1537-1551. PubMed ID: 33755739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.